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Stromal interaction molecule 1Store-operated calcium entry (SOCE) is a pathway that moves Ca2+ across the plasma membrane and
is mediated by two major proteins, STIM1 and Orai1. Here, we discovered that the cytoplasmic
domain of STIM1 is a target for calpains, a family of Ca2+-activated proteases. We found that calpain
cleavage of STIM1 serves to control its cellular abundance and was noticeably increased under con-
ditions of cellular stress and apoptosis. Dysregulation of STIM1 levels has been reported to have
human disease consequences and our results suggest a mechanism for controlling STIM1
abundance.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction functional STIM1 is associated with severe combined immunodefi-Ca2+ ions serve as versatile intracellular messengers; as such,
the cell has evolved various pathways to properly control the
movement of Ca2+ ions across various membranes and the accu-
mulation of ions within cellular organelles. One such pathway is
store-operated calcium entry (SOCE), which couples depletion of
ER luminal Ca2+ stores with Ca2+ influx across the plasma mem-
brane [1]. SOCE is mediated by two key proteins: stromal interac-
tion molecule 1 (STIM1), an ER transmembrane protein serving as a
Ca2+ store sensor [2,3]; and calcium release-activated calcium
channel (Orai) family membrane proteins, which serve as plasma
membrane Ca2+ channels [4]. Structurally, STIM1 can be separated
into several domains: a luminal domain, containing a Ca2+-binding
EF hand and a sterile-a-motif (SAM) [5]; a transmembrane
domain; and a cytoplasmic domain, containing several coiled-coil
domains, regions rich in serines and prolines, and a region rich in
lysines [6]. Initiation of SOCE occurs via Ca2+ dissociation from
the luminal domain of STIM1, leading to homooligomerization of
STIM1 [7]. The cytoplasmic coiled-coil domains of STIM1 are
thought to further mediate the oligomerization of STIM1 as well
as mediate direct contact between STIM1 and Orai1 [8]. Addition-
ally, the cytoplasmic domain is implicated in controlling the stabil-
ity and turnover of STIM1; STIM1 lacking its cytoplasmic domain is
noticeably less stable than is wild-type STIM1 [9]. STIM1 and SOCE
have been implicated in several different disease states: non-ciency [10], while increased STIM1 levels and SOCE have been
linked to increased metastatic behavior in breast cancer [11].
Calpains are a family of Ca2+-sensitive, neutral pH proteases;
there are fourteen known isoforms in humans, with the best-
characterized and most ubiquitously expressed being CAPN1 and
CAPN2 [12]. These both exist as heterodimers, consisting of a large
catalytic subunit and a small regulatory subunit, CAPN4, common
to CAPN1 and CAPN2 [12]; deletion of the gene encoding CAPN4,
CAPNS4, renders both CAPN1 and CAPN2 catalytically inactive
[13]. While calpain cleavage is known as a highly regulated event,
it does not occur at a rigidly defined site within a protein’s amino
acid sequence, but instead is dependent upon the primary sequence
as well as secondary [14] and three-dimensional structure [15].
In this study, we describe cleavage of STIM1 both under
endogenous conditions and in response to cell stress events. When
calpain activity was inhibited, STIM1 cleavage was significantly
reduced. Cleavage took place over a time course of hours to days,
suggesting it does not occur at sufficient speed as to serve as a
direct regulator of the process of SOCE. Instead, we propose that
STIM1 is targeted for calpain cleavage as a mechanism to regulate
the steady state levels of STIM1 within the cell. Furthermore,
STIM1’s susceptibility to calpain cleavage leads to enhanced STIM1
degradation during the progression of apoptosis.
2. Materials and methods
2.1. Protein synthesis, cell culture, SDS–PAGE, and immunoblotting
STIM1C protein was synthesized as described previously [16]:
cDNA encoding the cytoplasmic domain of STIM1 (residues 271–
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Fig. 1. STIM1 is cleaved by calpains. (A) STIM1/MEFs were transfected with a vector encoding YFP-STIM1 and left untreated or treated with 500 nM MG132 (MG). Lysates
were separated via SDS–PAGE, and immunoblotted for GFP and GAPDH (loading control). MG132 treatment increased levels of lower molecular fragments of YFP-STIM1
(indicated by arrowheads). (B) Wild-type MEFs were left untreated or treated with 500 nM MG132 (MG). MG132 treatment increased abundance of lower molecular weight
STIM1 fragments (indicated by arrowheads). c-Tubulin served as a loading control. (C) STIM1C, purified from E. coli, was incubated with calpain protein in the presence of
Ca2+ for time points up to 10 min as indicated in the Figure. Reactions were stopped by addition of sample loading buffer, after which samples were separated via SDS–PAGE
and stained with Coomassie blue. Addition of CAPN1 led to cleavage of STIM1C almost immediately, as shown by diminished levels of full-length STIM1C and the presence of
new bands with increased electrophoretic mobility as compared to the full-length STIM1C (indicated by arrowhead). (D) Wild-type and CAPN4/ fibroblasts were transfected
with a vector encoding YFP-STIM1 and left untreated, or treated with MG132 (400 nM or 1600 nM), as indicated. Lysates were separated via SDS–PAGE and probed with
antibodies against GFP. Immunoblotting for GFP shows some cleavage of YFP-STIM1 under all conditions (indicated by arrowhead), with a marked increase at the higher
MG132 concentration. Conversely, much less cleavage is seen in the absence of CAPN4, even when treated with 1600 nM MG132. c-Tubulin served as a loading control. (E)
Wild-type and CAPN4/ fibroblasts were left untreated or treated with 500 nM MG132. MG132 increases production of lower molecular weight bands in wild-type cells but
not in calpain-deficient cells. c-Tubulin served as a loading control. (F) STIM1/MEFs were transfected with a vector encoding YFP-STIM1 and either empty vector or a vector
encoding human calpastatin (CAST). Cells were then left untreated or treated with 500 nM MG132 (MG). Lysates were separated via SDS–PAGE and probed with an antibody
against GFP. Co-expression of CAST inhibits production of lower molecular weight YFP-STIM1 fragments. Western blot against GAPDH served as a loading control. (G)
Quantification of data in (F).
D. Prins, M. Michalak / FEBS Letters 589 (2015) 3294–3301 3295685) was generated via PCR-driven amplification using a STIM1-
pCMV6-XL5 plasmid as template. The cDNA product was cloned
into a pBAD/gIII Escherichia coli expression vector; recombinant
STIM1C was expressed in E. coli and purified from lysates using
Ni–NTA affinity column chromatography [17].Generation and characterization of STIM1/ cells were
described earlier [16]. Cells were transfected with expression vec-
tors encoding YFP-STIM1 and/or CAST using the Neon transfection
system (Invitrogen). Protein concentration was estimated using a
Lowry-based protein assay. SDS polyacrylamide gel electrophore-
Table 1
Predicted calpain cleavage sites within STIM1.
Algorithm Score (arbitrary
units)
Cleavage site
(after)
Sequence
SitePrediction,
CAPN1
1269 637 RALQAS
1212 420 SEVTAA
445 496 PSLQSS
SitePrediction,
CAPN2
630 496 PSLQSS
424 584 KELREG
346 637 RALQAS
http://calpain.org 0.14 637 RALQAS
0.14 584 KELREG
Online algorithms (SitePrediction: http://www.dmbr.ugent.be/prx/bioit2-public/
SitePrediction/index.php; http://calpain.org) and the sequence of human STIM1
(NCBI RefSeq NM_003156.3) were used to predict potential calpain cleavage sites
within STIM1.
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as described previously [16]. Antibodies used were: GFP (Abcam);
STIM1 (generated in the laboratory); GAPDH, c-tubulin, and b-
tubulin (Pierce Antibodies); calnexin (Enzo Life Sciences); Orai1
(H-46, Santa Cruz) and PARP (Cell Signaling Technology). All chem-
icals were from Sigma–Aldrich (St. Louis, USA).
2.2. Cytoplasmic Ca2+ measurements
Cytoplasmic Ca2+ concentrations in bulk cell populations were
measured using Fura2-acetoxymethyl ester (Fura2-AM) using pre-
viously described protocols [18]. Measurements were conducted
using a Photon Technology International instrument with excita-
tion wavelengths of 340 nm/380 nm and an emission wavelength
of 510 nm. Single cell cytoplasmic Ca2+ concentrations were mea-
sured using a previously described protocol [16]. A perfusion sys-
tem was used to alternately expose the cells to Ca2+-free buffer
(+1 mM EGTA) and Ca2+-containing buffer (+2 mM CaCl2).
3. Results
3.1. The cytoplasmic domain of STIM1 is a target for proteolytic
cleavage
During experiments involving immunoblots probed for
N-terminally tagged YFP-STIM1, we noticed the presence of pro-
tein bands at a lower molecular weight than full-length YFP-
STIM1 that were still recognized by an antibody against YFP. We
hypothesized that these YFP-STIM1 fragments were produced by
the regulated proteolytic cleavage of STIM1 followed by proteaso-
mal degradation. The sizes of the fragments and their maintenance
of the N-terminal YFP tag were consistent with cleavage of STIM1
within its long cytoplasmic domain. We therefore treated STIM1/
mouse embryonic fibroblasts (MEFs) expressing N-terminally
tagged YFP-STIM1 with MG132, a proteasomal inhibitor. Indeed,
we observed an increase in the levels of YFP-STIM1 fragments, sug-
gesting that STIM1 is a target for regulated cleavage (Fig. 1A). We
repeated this experiment in wild-type cells and probed for endoge-
nous STIM1 using an antibody against the N-terminus of STIM1.
We found very similar results: treatment of cells with MG132 led
to increased levels of lower molecular weight fragments of STIM1
(Fig. 1B).
We next aimed to identify the protease or proteases responsible
for the cleavage of STIM1. We used several online algorithms to
scan the amino acid sequence of STIM1 for predicted calpain cleav-
age sites, with results summarized in Table 1. As these algorithms
identified numerous calpain cleavage sites within STIM1, we
decided to further investigate calpains.We first developed a STIM1 expression construct we named
STIM1C, which encoded all the cytoplasmic amino acid residues
of STIM1; expressed this protein in, and purified it from, E. coli, fol-
lowed by incubation with commercially purchased calpain protein
in the presence of calcium to test for cleavage of STIM1C. This
in vitro system was able to recapitulate cleavage of STIM1C,
suggesting that the in vivo cleavage of STIM1 may be due to the
activity of calpains (Fig. 1C).
To further pinpoint a role for calpains, we obtained cells defi-
cient in the regulatory subunit of calpains (CAPN4/ cells) and their
wild-type counterparts and transfected these cells with YFP-STIM1.
We found that accumulation of both YFP-STIM1 and endogenous
STIM1 fragments was markedly reduced in calpain-deficient cells
(Fig. 1D and E). Finally, we co-expressed YFP-STIM1 and calpastatin
(CAST), a protein inhibitor of calpains, in the same cells and treated
these cells with MG132. Again, inhibition of calpains reduced the
cleavage of YFP-STIM1 (Fig. 1F and G). We therefore concluded that
the cleavage of STIM1 is by calpains.
3.2. STIM1 cleavage does not modulate store-operated calcium entry
After observing that calpains cleave STIM1, we aimed to deter-
mine its physiological significance. Our hypothesis was that calpain
cleavage of STIM1 may serve as a shutdown mechanism for SOCE,
with Ca2+ entry via Orai1 activating calpains to cleave STIM1, neu-
tralizing STIM1 activation of Orai1 and thus terminating SOCE. We
therefore measured SOCE in wild-type and calpain-deficient cells,
using a standard Fura2 protocol. Cells were treated with thapsi-
gargin (to deplete ER Ca2+ stores, stimulating STIM1 movement to
punctae) followed by external CaCl2 (to initiate SOCE). Ca2+ eleva-
tions due to thapsigargin treatment were very similar between
wild-type and calpain 4-deficient MEFs, suggesting that calpain
deficiency has no effect on the amount of Ca2+ stored within the
ER (Fig. 2A). After Ca2+ addback, SOCE was significantly higher in
the absence of calpains than in wild-type cells, both in terms of
peak Ca2+ level reached and the rate of Ca2+ entry (Fig. 2B). How-
ever, SOCE was still shut down in the absence of calpains. Ca2+
extrusion was higher in calpain-deficient cells, which may be
related to higher plasma membrane Ca2+ ATPase (PMCA) activity,
as calpains have been shown to cleave PMCA to inactivate it [19].
We next designed an experiment to monitor multiple cycles of
SOCE to more precisely determine if calpain cleavage of STIM1 acts
to modulate SOCE. We grew cells (wild-type or calpain 4-deficient)
on glass cover slips, loaded cells with Fura2, and monitored Fura2
fluorescence using a microscope equipped with a perfusion system,
allowing us to flow various buffers (with EGTA or with CaCl2) over
the cells. By changing back and forth from Ca2+-free to
Ca2+-containing buffers, we could measure multiple cycles of SOCE
in individual cells. If STIM1 is being cleaved immediately after
SOCE, we hypothesized that each successive calcium entry would
be lower. However, in wild-type cells, we did not see a deteriora-
tion of SOCE over time: each cycle of calcium entry and exit was
largely identical to the preceding cycle in both wild-type and
calpain-deficient cells (Fig. 2C). Quantification shows that the
amplitude of SOCE is statistically indistinguishable when compar-
ing the first and sixth cycles of SOCE in both wild-type and
calpain-deficient cells (Fig. 2D). Calpain-deficient cells exhibited
significantly higher and faster SOCE as well as faster calcium clear-
ance from the cytoplasm, as was seen in bulk cell Fura2
measurements.
As a final experiment to determine if calpain cleavage of STIM1
might act during SOCE in order to modulate SOCE directly, we
measured STIM1 cleavage over the time frame of two hours. We
added thapsigargin to cells for time points from 0 to 120 min and
looked for the characteristic STIM1 banding pattern. However, no
accumulation of lower molecular weight STIM1 fragments was
D. Prins, M. Michalak / FEBS Letters 589 (2015) 3294–3301 3297observed (Fig. 2E), suggesting that STIM1 cleavage does not occur
within this limited time frame. Along with our previous results
looking at SOCE directly, this supported a model in which STIM1
cleavage does not act to directly modulate SOCE.
3.3. Calpains cleave STIM1 to control its steady state levels
Intriguingly, we did observe that calpain-deficient cells had
higher store-operated calcium entry than did their wild-type coun-
terparts (Fig. 2A and B). We sought another explanation for this dif-
ference, hypothesizing that calpain cleavage of STIM1 mayA
C
D E
Fig. 2. Calpain affects store-operated calcium entry. (A) Wild-type and CAPN4/ fibrob
treated with 1 lM thapsigargin (TG) to deplete ER Ca2+ stores and then 2 mM external C
and faster store-operated calcium entry than did wild-type cells. Traces represent an ave
(SOCE) were calculated based on data in (A). CAPN4/ cells had significantly faster calci
type and CAPN4/ fibroblasts were grown on glass cover slips and loaded with Fura2-AM
to Ca2+-containing and Ca2+-free buffers in succession in order to measure multiple cycles
No significant diminishment of SOCE was seen over multiple cycles. (D) Quantification of
and 6th cycles. (E) Wild-type cells were treated with 1 lM thapsigargin for time points
STIM1 and c-tubulin as a loading control. No STIM1 cleavage was seen over this time pmaintain its equilibrium levels. When we compared levels of
STIM1 in wild-type and calpain-deficient cells, we found STIM1
to be noticeably more abundant in the absence of calpains
(Fig. 3A and B), which would account for increased SOCE. Overall
Orai1 levels were similar between both cell types, with some vari-
ations that may be due to altered glycosylation (Supp Fig. 1A).
We next compared the levels of STIM1 in the presence and
absence of calpain activity via treatment with cycloheximide to
halt protein translation. Incubation of wild-type cells with cyclo-
heximide for 24 h shows a significant decrease in STIM1 protein
levels, while calpain-deficient cells have a noticeably smallerB
lasts were loaded with Fura2-AM dye to measure cytoplasmic calcium. Cells were
aCl2 was added (Ca2+) to induce SOCE. CAPN4/ fibroblasts had significantly higher
rage of 6 separate experiments. (B) Maximum rates of store-operated calcium entry
um entry than did wild-type cells (WT: 108 ± 8; KO: 148 ± 12; P = 0.007). (C) Wild-
dye. As shown in the figure, after treatment with thapsigargin, cells were subjected
of SOCE. Traces represent an average of 8 cells from 3 separate biological replicates.
data in (C). SOCE amplitude was statistically indistinguishable when comparing 1st
up to 120 min, as indicated. Lysates were separated via SDS–PAGE and probed for
eriod.
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Fig. 3. STIM1 turnover is controlled by calpains. (A) Immunoblots probing for STIM1 in lysates from wild-type and CAPN4/ fibroblasts show elevated levels of STIM1 in the
absence of calpain activity. (B) Quantification of data in (A) **indicates statistical significance at P < 0.01. (C) Wild-type and CAPN4/ fibroblasts were left untreated or treated
with 30 lg/ml cycloheximide to inhibit protein synthesis, allowing for monitoring of protein turnover. While STIM1 levels diminished after cycloheximide treatment in wild-
type cells, STIM1 levels remained unchanged in CAPN4/ cells. (D) Quantification of data in (C) **indicates statistical significance at P < 0.01 (WT vs. WT CHX). Ns, not
significant (P = 0.6). (E) STIM1/ MEFs were transfected with YFP-STIM1 alone or YFP-STIM1 and CAST, then subjected to cycloheximide treatment for 8, 16, or 24 h.
Immunoblots probed with anti-GFP antibodies showed that presence of lower molecular weight fragments of YFP-STIM1 was increased over time as YFP-STIM1 was cleaved.
Co-expression of CAST noticeably decreased the presence of these lower molecular weight fragments. c-Tubulin served as a loading control. (F) Wild-type MEFs were
transfected with zeocin plasmid alone or zeocin and CAST expression vectors, then subjected to cycloheximide treatment for 8, 16, or 24 h. Immunoblots probed with anti-
STIM1 antibodies showed that full-length STIM1 levels decreased over cycloheximide treatment time course, but this decrease can be ameliorated by expression of CAST.
Immunoblots for calnexin (CNX) are included to demonstrate that its turnover is unaffected by CAST. c-Tubulin served as a loading control. (G) Wild-type MEFs were
transfected with zeocin plasmid alone or zeocin and CAST expression vectors. Lysates demonstrate that expression of CAST increased STIM1 levels by approximately 40%. (H)
Quantification of data in (G). **Indicates statistical significance at P < 0.01.
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Fig. 4. Calpain cleavage is elevated in apoptotic cells. (A) Wild-type MEFs were treated with 500 nM MG132, 50 lM PD150606, or both, as indicated. After 18 h of treatment,
lysates from adherent (A) and non-adherent (NA) cells were harvested independently, separated via SDS–PAGE, and immunoblotted as indicated. For PARP, (⁄) represents full-
length PARP, a marker of non-apoptotic cells; (⁄⁄) represents cleaved PARP, a marker of apoptotic cells. STIM1 cleavage was higher in non-adherent, apoptotic cells as
compared to adherent, non-apoptotic cells. Similarly to results with YFP-STIM1, this cleavage can be reduced by inhibition of calpains. (B) STIM1/ MEFs were transfected
with YFP-STIM1 alone or YFP-STIM1 and calpastatin (CAST). Cells were then left untreated or treated with 500 nM MG132, as indicated; 16 h after treatment, adherent (A)
and non-adherent (NA) cells were harvested separately. CAST expression reduced YFP-STIM1 cleavage; this effect was particularly noticeable in non-adherent, apoptotic cells.
(C) Quantification of data in (C). (D) Wild-type cells were treated with 500 nM MG132 and/or 25 lM zVAD-FMK-OMe, as indicated; 16 h after treatment, adherent (A) and
non-adherent (NA) cells were harvested separately. zVAD-FMK-OMe treatment was able to reduce STIM1 cleavage; this effect was particularly noticeable in non-adherent,
apoptotic cells. (E) Wild-type and ORAI1/MEFs were left untreated or treated with 500 nM MG132, 20 lM ionomycin, or both, as indicated. After 18 h of treatment, lysates
were harvested, separated via SDS–PAGE, and immunoblotted as indicated. Ionomycin induced cleavage of STIM1 in both wild-type and Orai1-deficient cells, suggesting
Orai1 is primarily required for its role as a Ca2+ channel.
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levels, STIM1 levels decrease by approximately 60% in wild-type
cells but only 10% in calpain-deficient cells, suggesting that
calpains control, at least in part, STIM1 turnover (Fig. 3C and D).
We performed further cycloheximide chase experiments over
various time points in cells expressing either YFP-STIM1 alone or
YFP-STIM1 and CAST together. Consistently with our results for
endogenous STIM1, YFP-STIM1 levels showed a gradual diminish-
ment over the time course of cycloheximide treatment with con-
current accumulation of lower molecular weight cleavageproducts. Co-expression of CAST was somewhat able to reduce
the loss of YFP-STIM1 levels over cycloheximide treatment and
thus led to lower levels of YFP-STIM1 cleavage products – without
CAST, approximately 40% of YFP-STIM1 was cleaved, while only
30% was cleaved with CAST (Fig. 3E). Stronger results were seen
when comparing loss of endogenous STIM1 in wild-type cells
and cells expressing calpastatin (Fig. 3F).
Finally, we aimed to determine if expression of calpastatin can
increase STIM1 abundance, as our hypothesis would expect. We
therefore transfected wild-type cells with a plasmid encoding
3300 D. Prins, M. Michalak / FEBS Letters 589 (2015) 3294–3301zeocin resistance cassette alone or the zeocin resistance cassette
plasmid in combination with a calpastatin plasmid, with the inten-
tion of establishing stable cells. After using 400 lg/ml of zeocin to
select for cells that were successfully transfected, we maintained
cells in culture in the presence of 200 lg/ml for ten days, then took
cell lysates to measure STIM1 abundance (Fig. 3G). We found that
expression of calpastatin led to an increase of approximately 40%
in STIM1 levels (P = 0.01) (Fig. 3G and H). Therefore, we concluded
that one reason calpains act upon STIM1 is as a mechanism for the
regulation of its steady state levels.
3.4. STIM1 cleavage is enhanced in apoptotic cells
We next tested a third hypothesis: that STIM1 cleavage may
occur during the progression of apoptosis. We observed that treat-
ing cells with MG132 overnight often led to their detachment from
cell culture dishes, an event that correlates with the onset of apop-
tosis. Furthermore, in addition to inhibiting the proteasome,
MG132 has been shown to stimulate apoptosis via activation of
c-Jun N-terminal kinase (JNK1) [20]. We repeated our previous
experiments, but separately collected adherent and non-adherent
cells, using cleavage of poly ADP ribose polymerase (PARP) as a
marker for apoptosis. STIM1 cleavage was significantly enhanced
in apoptotic cells and could be inhibited by the calpain inhibitor
PD150606 (45% reduction in the 65kDa protein band), indicating
a role for calpains. PD150606 treatment did not affect PARP cleav-
age (Fig. 4A). YFP-STIM1 was also cleaved in response to another
apoptotic agent, brefeldin A (Supp Fig. 1B).
We next transfected cells with a vector encoding YFP-STIM1
alone or vectors encoding YFP-STIM1 and CAST, treated with
MG132, and collected adherent and non-adherent cells separately.
As shown previously, non-adherent cells showed much higher
levels of YFP-STIM1 cleavage than did adherent cells. Non-
adherent cells also expressing CAST showed noticeably lower accu-
mulation of YFP-STIM1 lower molecular weight fragments, indicat-
ing that these cleavage fragments are in fact due to calpain activity
(Fig. 4B). These data were quantified in Fig. 4C: CAST expression
increased the abundance of full-length YFP-STIM1 and decreased
the abundance of the 60kDa fragment.
Caspases are another family of proteases activated during apop-
tosis; additionally, there is evidence of crosstalk between caspase
and calpain pathways. For example, during apoptosis in HL-60
cells, caspase activation occurs upstream of calpain activation
[21]. We first used the online algorithm Cascleave to search for cas-
pase cleavage sites, but found no caspase cleavage sites within full-
length STIM1, pointing against direct cleavage by caspases [22].
We therefore used zVAD-FMK-OMe, a cell-permeable general cas-
pase inhibitor, in conjunction with MG132 to look for any effect on
the cleavage of STIM1. We found that inhibition of caspases signif-
icantly reduced the production of lower molecular weight STIM1
cleavage products (Fig. 4D). As STIM1 has no caspase cleavage sites
within its sequence, we did not favor a model where caspases
themselves cleave STIM1. Rather, we concluded that calpains were
acting downstream of caspases, and therefore caspase inhibition
prevented calpain activation, thus abrogating STIM1 cleavage.
3.5. Orai1 is required for cleavage of STIM1
Calpains are calcium-activated; therefore, we asked how the
cell elevates cytoplasmic Ca2+ levels in order to stimulate STIM1
cleavage. A logical candidate was Orai1, as it is intimately involved
with STIM1 in controlling cytoplasmic Ca2+. We obtained Orai1-
deficient cells [23] and repeated our previous experiments com-
paring cleavage of endogenous STIM1 in cells with or without
Orai1. We found that after overnight treatment with MG132,
Orai1-deficient cells showed no accumulation of lower molecularweight STIM1 fragments. We next treated cells with MG132, iono-
mycin or both, to test if pharmacological provision of Ca2+ could
restore calpain cleavage to Orai1-deficient cells. We found that
ionomycin, either alone or with MG132, induced STIM1 cleavage
in both wild-type and ORAI1/ cells, leading us to conclude that
Orai1 is required in its role as a Ca2+ channel (Fig. 4E).4. Conclusions
Here, we discovered that STIM1 is a target for calpain, a Ca2+-
dependent protease. Our results point to a role of calpain cleavage
of STIM1 in controlling the equilibrium levels of STIM1 and within
apoptosis. A previous report indicated that STIM1 had a half-life of
approximately 19 h and that its stability was dependent on the
presence of its cytoplasmic, coiled-coil domains [9]. We therefore
hypothesized that calpain cleavage of STIM1 within its cytoplasmic
domain may destabilize STIM1, promoting its turnover. Indeed, in
cells lacking calpain activity, resting STIM1 levels were elevated as
compared to wild-type cells. This also manifested in changes in
SOCE: an increase in the amount of STIM1 was reflected in an
increase in SOCE. Furthermore, inhibition of protein synthesis via
cycloheximide led to a decrease in the abundance of STIM1 in
wild-type cells, but this decrease could be significantly amelio-
rated by inhibition of calpains with CAST, indicating that the previ-
ously described turnover of STIM1 can be largely attributed to
calpains. Finally, long-term expression of CAST in wild-type cells
was able to increase STIM1 levels as compared to cells without
CAST, further supporting our assertion that calpain cleavage of
STIM1 is a mechanism by which the cell can control STIM1 levels.
In light of the fact that STIM1 cleavage was enhanced after
extended drug treatments to induce cell stress, we considered a
role for apoptosis in controlling STIM1 cleavage. STIM1 cleavage
was elevated in non-adherent cells undergoing the late stages of
apoptosis, suggesting that the degradation of STIM1 occurs con-
comitantly with apoptosis. Despite possessing no caspase cleavage
sites, treating cells with the pan-caspase inhibitor zVAD-FMK-OMe
significantly reduced STIM1 cleavage in response to MG132 treat-
ment. We believe this result was due to previously described cross-
talk between caspases and calpains, where caspase activation is
known to be upstream of calpain activation during the progression
of apoptosis [21]. In further support, CAST was a potent inhibitor of
STIM1 cleavage though, to our knowledge, it has never been
described as an inhibitor of caspases. In fact, caspases have been
shown to cleave CAST itself [24]. We also found that STIM1 cleav-
age was severely reduced in the absence of Orai1, implicating Orai1
as the source of Ca2+ required to activate calpains.
STIM1 is a key constituent of intracellular Ca2+ signaling and has
been a target of intensive research due to its roles in numerous
pathways implicated in disease [25]. Artificially lowering the levels
of STIM1 has been shown to reduce breast cancer metastasis [11],
and interestingly, in some cases, increased expression of CAST has
linked to lymphovascular invasion in breast cancer [26]. It is there-
fore feasible that there may be a link between calpain activity and
STIM1 levels in invasive breast cancer. Here, we show that calpain
activity serves as a mechanism to control endogenous STIM1
levels. Overall, we suggest that the interplay between STIM1 and
calpains may play a heretofore unknown role in the control of
SOCE.
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